Table 2.
Parameters used in the study, children ≥ 5 years and adults
| EPIDEMIOLOGICAL PARAMETERS | Source1 | |
|---|---|---|
| Malaria attributable fevers (MAF)/febrile patients (dry season) | 1.7% | Primary |
| Malaria attributable fevers (MAF)/febrile patients (rainy season) | 25.1% | Primary |
| Malaria parasite density > 40,000/μL (both seasons) | 36.8% | Primary |
| Death rate treated MAF, high parasite density | 0.0% | Primary |
| Excess death rate untreated MAF, high parasite density | 0.4% | Assumption |
| Excess death rate untreated MAF low parasite density | 0.0% | Assumption |
| Excess death rate untreated MAF in RDT neg | 0.0% | Assumption |
| Death rate treated NMFI | 0.84% | Primary |
| Proportion of potentially fatal non malarial fever (PFNM) | 20% | Assumption |
| Excess death rate untreated PFNM | 7% | Assumption |
| CASE MANAGEMENT, PRESUMPTIVE BRANCH, ADULTS | ||
| Anti-malarial treatment among MAF | 97% | Primary |
| Anti-malarial treatment among MAF, high parasite density | 97.3% | Primary |
| Anti-malarial treatment among MAF, low parasite density | 97% | Assumption |
| Anti-malarial treatment among those treated with antibiotics | 79.3% | Primary |
| Anti-malarial treatment among those not treated with antibiotics | 94.8% | Primary |
| Antibiotic treatment among NMFI | 56.1% | Primary |
| Antibiotic treatment among PFMN | 90% | Assumption |
| Antibiotic treatment among patients presumptively treated for malaria | 47.1% | Primary |
| Antibiotic treatment among PFMN presumptively treated for malaria | 86% | Assumption |
| Antibiotic treatment among patients not presumptively treated for malaria | 80.8% | Primary |
| Antibiotic treatment among PFMN not treated for malaria | 99% | Assumption |
| CASE MANAGEMENT, RDT, ADULTS | ||
| Anti-malarial treatment among RDT+, high parasite density (hpd) | 100% | Primary |
| Anti-malarial treatment among RDT+, low parasite density (lpd) | 96.4% | Primary |
| Anti-malarial treatment among RDT- | 10% | Assumption |
| Antibiotic treatment among RDT+ | 42.5% | Primary |
| Antibiotic treatment among PFNM RDT+ | 86% | Assumption |
| Antibiotic treatment among RDT- | 77.4% | Assumption |
| Antibiotic treatment among PFNM RDT- | 98.6% | Assumption |
| RDT ACCURACY, ADULTS | ||
| RDT sensitivity, malaria attributable fever (MAF), lpd, dry season | 91.6% | Primary |
| RDT specificity, malaria attributable fever (MAF), dry season | 78.7% | Primary |
| RDT sensitivity, malaria attributable fever (MAF), lpd, rainy season | 95.3% | Primary |
| RDT specificity, malaria attributable fever (MAF), rainy season | 77.4% | Primary |
| RDT sensitivity, MAF, high parasite density | 99% | Primary |
| COSTS, ADULTS | ||
| Cost of RDT | 0.71 | (ref. 26) |
| Cost of anti-malarial treatment, Coartem (average, €) | 2 | (ref. 26) |
| Cost of antibiotic treatment (average, €) | 0.4 | Estimate |
| Life Value (€) corresponding to 25 US $*YLL | 525 | (see text) |
| Life Value (€) corresponding to 150 US $*YLL | 3150 | (see text) |
1 Primary data obtained from previous RCT (ref. 15) and from previous assessment of the RDT accuracy (ref. 14); assumptions based on estimates from primary data, expert opinion and previous literature (see explanation in text)